Immuno-Oncology (I-O) Market, by Therapy (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, , and CAR-T Cell Therapy), by Therapeutic Area (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancers, Melanoma and Blood Cancers) - Global Industry Insights, Trends and Forecast (2017-2025)

Created On: Aug-2018
Report ID: IR161
Format: PDF

Immuno-oncology is a unique therapy which focuses on strengthening body’s immune system to fight against cancer. These therapies are different from conventional therapies like radiation and chemotherapy as it does not create hindrance in the functioning of normal or healthy cells and are comparatively less toxic. Immuno-Oncology market is expected to grow at a faster pace in the forecast period as it holds the potential to attack and destroy the cancerous cells resulting in extended lifespan of patient suffering from various types of cancers. Some of the immuno-oncology therapies that are commercially available include Nivolumab, Gardasil, Rituximab, Blinatumomab, Iplimumab, Kymriah and Proleukin.

Market Dynamics

The immuno-oncology market is expected to witness a steep rise in the forecast period and one of the primary factors for this growth is escalation in regulatory approval procedure of immuno-oncology drugs and increase in number of immuno-oncology therapy clinical trials. Increased recognition of patient assistance therapeutic programs due to increase in occurrence of various types of cancers also hold the potential to drive the market.  The arrival of several small and midsized healthcare companies and the increase in merger activities of large healthcare companies such as Bristol-Myers Squibb and Five Prime Therapeutics to develop and commercialize programs like ‘CSF1R antibody program’ assures a bright future of Immuno-Oncology market. 

Certain factors that can restrict the growth of immuno-oncology market in the forecast period includes the high production cost of immuno-oncology drugs such as Keytruda (US$ 2,250 for a vial of 50mg), restrictions on commercialization of certain drugs by government due to safety concern and side-effects caused by drugs or therapies post treatment. The lack of availability of resources and appropriate infra-structure to conduct clinical trials on immuno-oncology products in developing nations like India and China can also hinder the growth of the market in those regions.

Segment Analysis

In the recent years, immune checkpoint inhibitors have gained recognition as one of the most promising types of immunotherapy. Immune checkpoint inhibitors are drugs that blocks checkpoint molecules like cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) in order to destroy cancer cells. Regulatory and clinical approval to immune checkpoint inhibitor drugs like Opdivo and Keytruda by U.S. Food and Drug Administration and their application in treating melanoma in combination with Ipilimumab have been successful. TIM-3 (T-Cell immunoglobulin and mucin domain 3), which is in its very initial phase of study, is also expected to be the next potential molecule to be taken in account in order to produce an effective immuno checkpoint drug to eliminate the growth of cancer cells in body.

Monoclonal antibodies have also been identified as one of the most effective therapeutic agents to treat human cancer. Several conjugated and unconjugated monoclonal antibodies are in their study phase and have been anticipated to show positive results in treating cancer when combined with suitable agents. Anti-HER2/neu, an unconjugated monoclonal antibody is one such antibody which is being widely used in combination with chemotherapy agents to treat breast cancer.

The immuno-oncology therapy has been anticipated to be used in treatments of various types of cancer indications in upcoming years. In recent years, lung cancer, prostate cancer and breast cancer has become the most common cancer types. Around 269,000 new breast cancer cases are expected to be identified alone in U.S in the year 2018. Atezolizumab and Nivolumab are some of the effective immuno-oncology drugs that are being used in the treatment of non-small cell lung cancer and has shown positive results.

Regional Analysis

North America and Europe are anticipated to hold the largest revenue share in immuno-oncology market in the forecast period. The reason for the dominance of these regions can be contributed to the expansion of geriatric population in these regions, availability of resources and power of expenditure required to conduct clinical trials. Presence of healthcare giants like Bristol-Myers Squibb and Merck & Co. that have several immuno-oncology drugs in pipeline also stands to be one of the major reason which establish North-America as major revenue generator in the global scenario.

Global Market Players

Global market players that are operating in immuno-oncology drugs market are Merck & Co., Amgen, Inc. AstraZeneca Plc, Novartis International AG, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Gilead Sciences Inc, Sanofi S.A., Bavarian Nordic, Aduro BioTech, Celgene Corporation, Eli Lilly and Company, Johnson & Johnson, AbbVie, Inc., EMD Serono, Inc., Pfizer Inc., Prometheus Therapeutics & Diagnostics, Galena Biopharma, Incyte, ImmunoCellular Therapeutics and Celldex Therapeutics.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us